Oryzon Genomics S.A.

BME:ORY 주식 보고서

시가총액: €103.1m

Oryzon Genomics 관리

관리 기준 확인 2/4

Oryzon Genomics' CEO is Carlos Manuel Arjol, appointed in Jan 2000, has a tenure of 24.83 years. directly owns 4.61% of the company’s shares, worth €4.76M. The average tenure of the management team and the board of directors is 5.8 years and 9 years respectively.

주요 정보

Carlos Manuel Arjol

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기24.8yrs
CEO 소유권4.6%
경영진 평균 재임 기간5.8yrs
이사회 평균 재임 기간9yrs

최근 관리 업데이트

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oct 03
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%

Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Jun 09
Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch

Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Apr 04
Is Oryzon Genomics (BME:ORY) Using Too Much Debt?

Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Jul 24
Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts

Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

May 01
Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?

Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

Feb 26
Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?

If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

Jan 04
If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns

CEO

Carlos Manuel Arjol

24.8yrs

테뉴어

US$62,992

보상

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

리더십 팀

이름위치테뉴어보상소유권
Carlos Manuel Arjol
Co-Founder24.8yrsUS$62.99k4.61%
€ 4.8m
Enric Condomines
Director of Operations4.4yrs데이터 없음데이터 없음
Jordi Pey
Chief Scientific Officer3.8yrs데이터 없음데이터 없음
Xavier Ribera
Head of Internal Audit & Complianceno data데이터 없음데이터 없음
Emili Cortada
Chief Business Development Officerno data데이터 없음데이터 없음
Neus Bernado
Chief Intellectual Property Officer13.2yrs데이터 없음데이터 없음
Michael Ropacki
Chief Medical Officer of CNS3.8yrs데이터 없음데이터 없음
Sonia Paloma Bezon
Chief of Clinical Operations7.1yrs데이터 없음데이터 없음
Augusto Rubio
Secretaryno data데이터 없음데이터 없음

5.8yrs

평균 재임 기간

경험이 풍부한 관리: ORY's management team is seasoned and experienced (5.8 years average tenure).

이사회 구성원

이름위치테뉴어보상소유권
Carlos Manuel Arjol
Co-Founder23.8yrsUS$62.99k4.61%
€ 4.8m
Howard Fillit
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Isabel Aguilera Navarro
Independent Director9yrsUS$7.60k데이터 없음
Lori Kunkel
Member of Scientific Advisory Board6.8yrs데이터 없음데이터 없음
Manuel López-Figueroa
Lead Independent Director4.5yrs데이터 없음데이터 없음
Josep Echarri Torres
Director22.8yrsUS$6.52k1.98%
€ 2.0m
Tamara Maes
VP of the Board & President of Scientific Advisory Board24.8yrsUS$62.99k3.96%
€ 4.1m
Ramon Ramon
Independent Director9yrsUS$7.60k0.029%
€ 30.0k
Leon Hooftman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Antonio Melero
Independent Director9yrsUS$7.60k데이터 없음
Felipe Cardoso
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jose Molinuevo
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

9.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: ORY's board of directors are considered experienced (9 years average tenure).